Storia in 5 fonti

Why Is Regenxbio Stock Falling Monday? - Regenxbio (NASDAQ:RGNX)

Regenxbio stock drops over 23% following an FDA clinical hold on its Hunter Syndrome gene therapy RGX-121 due to spine MRI findings.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo2 g fa

Why Is Regenxbio Stock Falling Monday? - Regenxbio (NASDAQ:RGNX)

Regenxbio stock drops over 23% following an FDA clinical hold on its Hunter Syndrome gene therapy RGX-121 due to spine MRI findings.

originale

Timeline cronologica

lunedì 24 agosto 2026·biopharmadive.com
Safety concerns spur FDA to again halt testing of Regenxbio gene therapy
Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.
lunedì 24 agosto 2026·morningstar.com
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

endpoints.news

2 g fa

Regenxbio hit with another clinical hold for Hunter syndrome gene therapy

Regenxbio's RGX-121 Hunter syndrome gene therapy faces second clinical hold after spinal lumps found in 5 CAMPSIITE trial patients, sending $RGNX shares down 23%.

Leggi questa versione → originale

biopharmadive.com2 g fa

Safety concerns spur FDA to again halt testing of Regenxbio gene therapy

Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.

Leggi questa versione → originale

morningstar.com2 g fa

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Leggi questa versione → originale

statnews.com2 g fa

FDA pauses Regenxbio gene therapy trial again due to safety concerns

The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged.

Leggi questa versione → originale

lunedì 24 agosto 2026·

statnews.com

FDA pauses Regenxbio gene therapy trial again due to safety concerns

The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged.

lunedì 24 agosto 2026·

benzinga.com

Why Is Regenxbio Stock Falling Monday? - Regenxbio (NASDAQ:RGNX)

Regenxbio stock drops over 23% following an FDA clinical hold on its Hunter Syndrome gene therapy RGX-121 due to spine MRI findings.

lunedì 24 agosto 2026·

endpoints.news

Regenxbio hit with another clinical hold for Hunter syndrome gene therapy

Regenxbio's RGX-121 Hunter syndrome gene therapy faces second clinical hold after spinal lumps found in 5 CAMPSIITE trial patients, sending $RGNX shares down 23%.